How to Onboard a European Sterile Injectable CDMO for Commercial Manufacturing

Onboarding a Contract Development and Manufacturing Organisation for commercial sterile injectable manufacturing is one of the most consequential programme decisions a pharmaceutical or biotechnology company will make. A well-executed onboarding process delivers reliable, compliant, patient-ready supply. A poorly managed one introduces regulatory, quality and commercial risk that compounds over time and is rarely straightforward to reverse.

This guide maps nine structured phases of a European sterile injectable Contract Development and Manufacturing Organisation onboarding, from initial requirements definition through validated technology transfer and into steady-state commercial supply. At each phase, it identifies the key stakeholders, required data, timeline considerations and risk controls that development and operations leaders need to manage.

Adragos Pharma operates a multi-site sterile manufacturing cluster with facilities in Switzerland and France, supported by a partner facility in Norway and inspection and packaging services in Japan. Programmes are supported from early clinical manufacturing through large-volume global commercial supply under EU Good Manufacturing Practice and international regulatory frameworks.

Phase 1: Define Your Programme Requirements Before Approaching the Market

The first step in sterile injectable Contract Development and Manufacturing Organisation onboarding is to define your programme requirements with precision before approaching any prospective partner.

Without a clearly articulated product profile, due diligence becomes unfocused and vendor comparisons lack a common basis. Before issuing any Request for Information or Request for Proposal, development and operations leaders should document the following:

• Dosage form and primary container: liquid vial, lyophilised vial, prefilled syringe or ampoule, including target fill volume and container format
• Molecule class: small molecule or biological product
• Batch size range: expected volumes at launch, at peak commercial demand and across the product lifecycle
• Regulatory filing markets: European Medicines Agency, United States Food and Drug Administration or multi-regional submissions
• Sterility method: aseptic processing or terminal sterilisation
• Cold chain profile: ambient, refrigerated or frozen storage and distribution conditions
• Controlled substance requirements: schedule classification and associated handling certifications where relevant

This product profile document becomes the primary filter for Contract Development and Manufacturing Organisation shortlisting and the foundation of every technical conversation that follows.

Phase 2: Conduct Structured Due Diligence and Capability Screening

Selecting a sterile injectable Contract Development and Manufacturing Organisation requires structured due diligence that evaluates technical capability, regulatory certification, site capacity and quality culture before any formal on-site audit takes place.

Technical Capability Screening

Assess each prospective Contract Development and Manufacturing Organisation’s equipment and process capabilities against your defined product profile. Parameters to evaluate include:

• Aseptic barrier technology: Restricted Access Barrier System or isolator-based aseptic filling
• Lyophilisation capacity: freeze-dryer chamber size, loading and unloading automation and cycle development experience
• Fill line speed and batch size range: minimum and maximum vial, syringe or ampoule quantities per batch
• Aseptic Process Simulation compliance: frequency of media fill campaigns and historical outcomes
• Complex formulation handling: suspension re-homogenisation, emulsion and viscous liquid capability
• Single-use technology strategy: availability of single-use systems to reduce cross-contamination risk and cleaning validation burden
• Visual inspection systems: automated or semi-automated inspection capability

Adragos Jura in Switzerland provides aseptic fill-and-finish for liquid and lyophilised vials for both small molecules and biological products. The site is equipped with Restricted Access Barrier System technology, peristaltic and rotary piston pumps, lyophilisers at 3 m² and 9 m² capacity and a single-use strategy. There is no minimum batch size, with capacity up to 74,000 vials per batch and a three-month turnaround from order to batch including controlled drug handling. This makes the site well suited to early commercial programmes where batch size flexibility is critical.

For high-volume commercial supply, Adragos Maisons-Alfort in France provides high-speed aseptic filling at up to 540 units per minute for prefilled syringes and vials, 100% automated inspection at up to 600 units per minute and large automated freeze-dryer loading systems accommodating up to 74,000 vials, with total prefilled syringe capacity of up to 150 million units per year.

Regulatory Certification Review

A commercially viable sterile injectable Contract Development and Manufacturing Organisation must hold current Good Manufacturing Practice certification from the regulatory authorities relevant to your filing markets. At minimum, verify:

• Current European Medicines Agency certification for European Union supply
• Current United States Food and Drug Administration certification for United States market access
• Additional national authority certifications relevant to all intended launch markets

Adragos Jura holds certification from the European Medicines Agency, the United States Food and Drug Administration and Swissmedic. Adragos Maisons-Alfort is certified by 12 international health authorities. Adragos Livron holds European Union Good Manufacturing Practice certification alongside approval from France’s Agence nationale de sécurité du médicament et des produits de santé, France’s Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail and Korea’s Ministry of Food and Drug Safety.

Phase 3: Execute Site Qualification and GMP Auditing

Site qualification is a formal, documented evaluation confirming that the proposed facility meets the quality and compliance standards required for your programme before any manufacturing activities are initiated.

Pre-Audit Documentation Request

Before conducting an on-site audit, request and review the following from the prospective Contract Development and Manufacturing Organisation:

• Current Good Manufacturing Practice certificates from all applicable regulatory authorities
• Most recent regulatory inspection reports and formal responses, including Form FDA 483s and European Medicines Agency inspection findings where applicable
• Site Master File
• Quality Management System overview, covering deviation management, change control and corrective and preventive action processes
• Aseptic Process Simulation records from the preceding two to three years, including outcomes
• Environmental monitoring programme summaries and trend data
• Deviation and Out-of-Specification trending data
• Customer audit history and frequency

A Contract Development and Manufacturing Organisation that accommodates regular client audits demonstrates operational transparency. Adragos Jura conducts 12 client audits per year, reflecting an established and open quality culture.

On-Site Audit Scope

The audit should be structured across the following domains:

1. Cleanroom and aseptic environment: cleanroom classification, environmental monitoring programme and barrier technology in use
2. Equipment qualification status: Installation Qualification, Operational Qualification and Performance Qualification documentation for all critical equipment including filling lines, lyophilisers and inspection systems
3. Quality Management System: deviation management, Out-of-Specification handling, corrective and preventive action and change control processes
4. Analytical and stability capabilities: in-house quality control methods, stability chamber capacity and management of International Conference on Harmonisation-compliant stability programmes
5. Data integrity: electronic batch record systems, audit trail architecture and access control governance
6. Supply chain controls: raw material and primary packaging supplier qualification and management
7. Regulatory submission experience: history of supporting Marketing Authorisation Applications and managing post-approval change supplements or variations

The audit team should include representatives from quality assurance, regulatory affairs and technical operations. All findings should be risk-rated and formally documented before a supplier qualification decision is made.

Quality Agreement Execution

Following successful site qualification, a Quality Agreement must be executed before any manufacturing activity commences. This document defines responsibilities for batch release, deviation notification timelines, change control obligations and right-to-audit provisions for the duration of the programme.

Phase 4: Assemble the Technical Data Package

A complete and well-structured technical data package is the foundation of every successful sterile injectable technology transfer. Incomplete data packages are among the most common and avoidable causes of delay and process deviation during transfer.

The data package should be assembled by a cross-functional team and formally reviewed by the receiving Contract Development and Manufacturing Organisation before the technology transfer plan is finalised. Core elements are outlined below.

Data Package Element	Purpose
Master Batch Record (clinical or pre-commercial scale)	Establishes the manufacturing process baseline for transfer
Formulation composition and specifications	Defines Active Pharmaceutical Ingredient, excipients and container closure system
Analytical methods and validation reports	Enables method transfer and in-process testing at the receiving site
Process development summary reports	Documents critical process parameters, scale-up observations and process understanding
Container closure integrity data	Confirms primary packaging suitability for the product
Stability data (International Conference on Harmonisation-compliant)	Supports shelf life assignment and storage condition definition
Raw material specifications and supplier information	Enables raw material qualification at the receiving facility
Cleaning validation data	Supports cleaning procedure development where applicable
Quality Risk Assessment (Failure Mode Effects Analysis or equivalent)	Identifies critical quality attributes and process failure modes

A gap analysis should be conducted against this checklist before the technology transfer plan is agreed, with any outstanding elements assigned owners and resolution timelines.

Phase 5: Establish Stakeholder Governance and Programme Management

Effective programme governance is a direct determinant of onboarding success. Without clearly defined roles, decision rights and communication structures, even technically sound technology transfers stall or lose momentum at critical milestones.

Stakeholder Mapping

A Responsible, Accountable, Consulted and Informed matrix should be established at programme initiation and maintained throughout the onboarding lifecycle. This should cover representatives from both the sponsor organisation and the Contract Development and Manufacturing Organisation.

Sponsor-side stakeholders typically include:

• Programme or Project Manager
• Regulatory Affairs Lead
• Quality Assurance representative
• Supply Chain and Demand Planning Lead
• Commercial and Market Access representative
• Finance representative (for capital expenditure oversight and unit cost modelling)

Contract Development and Manufacturing Organisation-side stakeholders typically include:

• Dedicated Programme Manager or point of contact
• Quality Director
• Production Director
• Head of Supply Chain
• Regulatory Affairs support

Adragos Jura assigns a single dedicated point of contact to each programme from initiation through commercial supply. This structure maintains continuity across quality, production and supply chain activities and reduces the communication gaps that typically slow decision-making in multi-stakeholder programmes.

Governance Structures

Recommended governance cadences include:

• Operational Review Meetings (weekly or fortnightly): focused on batch scheduling status, raw material supply and resolution of open action items
• Technical Review Meetings (monthly): covering process performance, deviations and progress against technology transfer milestones
• Strategic Steering Committee (quarterly): senior representation from both organisations, reviewing programme risk, commercial supply readiness and capacity planning

A shared, milestone-based project plan with agreed escalation pathways and risk owners should underpin all governance layers.

Phase 6: Execute Technology Transfer from Clinical to Commercial Scale

Technology transfer for sterile injectable manufacturing is the structured process by which process knowledge, analytical methods and quality systems are moved from the originating site to the receiving Contract Development and Manufacturing Organisation, culminating in manufacturing readiness at commercial scale.

Technology transfer for sterile injectable products is technically demanding. Lyophilisation cycle translation, aseptic filling scale-up and container closure integrity verification each require systematic, documented approaches that cannot be accelerated without introducing risk.

Technology Transfer Plan

The technology transfer plan should define:

• Scope of transfer, covering manufacturing process steps, analytical methods and the stability programme
• Knowledge transfer activities, including technical workshops, process documentation review sessions and process walkthroughs
• Engineering and confirmatory batch strategy
• Critical process parameter and critical quality attribute definitions
• Acceptance criteria for each phase of the transfer
• Regulatory filing strategy for the receiving site

Engineering Batches

Engineering batches at the receiving facility verify that equipment, process parameters and materials perform consistently with originating site data. Key activities during this phase include:

• Filling line set-up and process parameter verification
• Lyophilisation cycle transfer and thermal mapping
• In-process testing against established specifications
• Container closure integrity testing
• Planning for Aseptic Process Simulation

Adragos Jura supports early commercial batch execution with a three-month order-to-batch cycle, including controlled substance handling, enabling sponsors to obtain initial engineering batch data and make informed decisions without extended lead times.

Analytical Method Transfer

Analytical methods used for product release and stability testing must be formally transferred to the receiving quality control laboratory. Method transfer activities include:

• Protocol preparation and bilateral agreement
• Side-by-side comparative testing at both the originating and receiving sites
• Statistical evaluation of results against pre-defined acceptance criteria
• Formal method transfer report and authorised sign-off

Adragos Jura provides in-house analytical capabilities including High-Performance Liquid Chromatography validation, sterility suitability testing, endotoxin suitability testing and bioburden suitability testing. These capabilities support the full scope of release and stability method transfer within the facility, reducing reliance on external contract laboratories during the transfer phase.

Phase 7: Complete Process Validation and Manage Regulatory Submissions

Process validation for commercial sterile injectable manufacturing confirms that the manufacturing process consistently produces product meeting its pre-determined specifications and quality attributes. It is a regulatory requirement for commercial supply and must be planned in parallel with regulatory submission activities.

Process Validation Stages

Consistent with International Conference on Harmonisation guidance and European Medicines Agency expectations, commercial process validation proceeds through three stages:

Stage 1: Process Design

Generation of process understanding through development, scale-up and engineering batch data, including critical process parameter and critical quality attribute characterisation.

Stage 2: Process Qualification

Demonstration of process control through Process Performance Qualification batches executed under commercial conditions, using commercial-scale equipment, materials and personnel.

Stage 3: Continued Process Verification

Ongoing statistical monitoring of process performance data during routine commercial manufacture, providing evidence that the process remains in a state of control throughout the product lifecycle.

Process Performance Qualification for sterile injectables typically involves consecutive batches at commercial scale, demonstrating fill volume consistency, container closure integrity, sterility assurance and, where applicable, lyophilisation cycle reproducibility.

Aseptic Process Simulation

Aseptic Process Simulation, also referred to as a media fill, replicates worst-case aseptic filling conditions using microbiological growth media in place of the drug product. Outcomes must meet European Medicines Agency and United States Food and Drug Administration acceptance criteria before commercial supply commences. Full Aseptic Process Simulation compliance is maintained across Adragos’ commercial sterile fill-finish manufacturing operations.

Regulatory Variation or Supplement Submission

Adding a new manufacturing site to an existing Marketing Authorisation requires submission of a post-approval change variation to the relevant regulatory authority. The classification of the variation under European Medicines Agency variation procedures determines the applicable review pathway.

Sponsor and Contract Development and Manufacturing Organisation regulatory affairs teams must coordinate to ensure that Process Performance Qualification data, validation reports and updated Chemistry, Manufacturing and Controls dossier sections are prepared concurrently and submitted without unnecessary delay. Early alignment on the regulatory filing strategy, prior to process validation execution, avoids the common pitfall of completing manufacturing activities before the submission package is ready.

Phase 8: Achieve Commercial Supply Readiness

Commercial supply readiness is reached when the Contract Development and Manufacturing Organisation can consistently manufacture and release batches at the volumes and frequencies required to meet commercial demand, supported by documented supply chain risk controls and an agreed batch release process.

Supply Chain Risk Assessment

Before transitioning to live commercial supply, a formal risk assessment should address:

• Single-source raw material dependencies: Active Pharmaceutical Ingredient suppliers and excipient sources with limited or no qualified alternatives
• Primary packaging supply risks: glass vials, rubber stoppers, aluminium crimp caps or prefilled syringe components
• Batch failure contingency planning: minimum successor batch scheduling, safety stock parameters and out-of-stock trigger points
• Demand volatility management: the scheduling flexibility available within the Contract Development and Manufacturing Organisation’s capacity planning model

Adragos operates a multi-site sterile manufacturing cluster incorporating Jura (Switzerland), Maisons-Alfort (France) and Livron (France), with a partner facility at Halden (Norway) providing Blow-Fill-Seal technology and intravenous bag manufacturing, and Kawagoe (Japan) providing visual inspection and packaging services for Japanese market entry. This network configuration allows programme-level flexibility and, where product profile and regulatory conditions permit, the option to route manufacturing across complementary sites.

Demand Planning Integration

The sponsor’s commercial and supply chain teams should integrate rolling demand forecasts into the Contract Development and Manufacturing Organisation’s scheduling process, agreeing on:

• Rolling forecast horizon and update frequency
• Minimum and maximum batch frequencies per planning period
• Safety stock targets and inventory replenishment parameters
• Lead time from batch initiation to released product at the sponsor’s distribution network

Batch Release Process Alignment

The batch release workflow must be fully documented and tested before commercial supply begins. This covers:

• Batch record review and completion by the Contract Development and Manufacturing Organisation’s Qualified Person
• Release testing completion and Out-of-Specification management procedures
• Certificate of Analysis issuance and handover to the sponsor
• Temperature-controlled logistics from the manufacturing facility to the sponsor’s distribution warehouse

Phase 9: Sustain Steady-State Supply Through Lifecycle Management

Steady-state commercial supply requires ongoing performance monitoring, proactive capacity planning and coordinated regulatory maintenance to sustain compliant and reliable supply across the full commercial lifetime of the product.

Performance Monitoring

A structured Key Performance Indicator framework at steady state should track, at minimum:

• Batch right-first-time rate
• Batch release cycle time versus target
• Schedule adherence to the agreed production calendar
• Deviation frequency and corrective and preventive action closure timeliness
• Out-of-Specification event rate
• Delivery performance versus forecast

Annual Periodic Product Quality Reviews, conducted as a minimum requirement under Good Manufacturing Practice regulations, provide a longitudinal view of process performance and inform structured continuous improvement decisions.

Change Control and Regulatory Maintenance

Post-approval changes to the manufacturing process, raw materials, primary packaging, equipment or facility configuration require structured change control management aligned with the Contract Development and Manufacturing Organisation’s Quality Management System and the applicable regulatory variation framework. Early engagement between sponsor and Contract Development and Manufacturing Organisation quality and regulatory affairs teams prevents unplanned supply disruptions resulting from inadequately managed regulatory submissions.

Lifecycle Capacity Planning

Demand profiles shift as products mature, generics enter the market or line extensions are introduced. Contract review cycles should include structured discussions on capacity reservation, batch size optimisation and equipment investment planning to ensure schedule reliability is maintained as programme volumes evolve.

How Adragos Pharma Supports Your Sterile Injectable Programme

Adragos Pharma is a customer-centric Contract Development and Manufacturing Organisation with seven Good Manufacturing Practice facilities across the EU, US and Japan and three centuries of collective pharmaceutical manufacturing experience across its global team. The Adragos sterile manufacturing cluster is structured to support programmes from early clinical development through large-volume commercial supply.

Adragos Jura, Switzerland

Adragos Jura provides over 25 years of aseptic fill-and-finish specialisation for liquid and lyophilised vials, supporting both small molecules and biological products. The site holds certification from the European Medicines Agency, the United States Food and Drug Administration and Swissmedic. Producing 200 clinical batches per year and having supported five successful commercial launches, the site accommodates batch sizes from no minimum up to 74,000 vials. A three-month order-to-batch turnaround, a single dedicated point of contact and full Aseptic Process Simulation compliance underpin every programme from clinical development through small-to-medium commercial scale.

Adragos Maisons-Alfort, France

Adragos Maisons-Alfort delivers over 77 years of sterile manufacturing experience in the large-scale commercial production of prefilled syringes and liquid and lyophilised vials. High-speed aseptic filling at up to 540 units per minute, 100% automated inspection at up to 600 units per minute and certification by 12 international health authorities support global commercial supply at scale. The facility operates with Clean-in-Place and Sterilise-in-Place systems and Restricted Access Barrier System technology, and maintains full Aseptic Process Simulation compliance.

Adragos Livron, France

Adragos Livron brings over 110 years of experience in sterile ampoule manufacturing, with 120 million units of annual capacity across four production lines, including two Restricted Access Barrier System-equipped aseptic lines. Both aseptic filling and terminal sterilisation are available, accommodating the stability requirements of over 100 molecules handled at the site.

Adragos Athens, Greece

Adragos Athens serves as a centre of excellence for pharmaceutical drug development, with over 150 electronic Common Technical Document dossier submissions and product approvals in more than 20 countries. Regulatory and development support includes High Potency Active Pharmaceutical Ingredient handling capability, available to sponsors from early development through to commercial dossier submission.

Beyond manufacturing execution, Adragos invests in programme outcomes through a co-ownership of success model, providing full attention and dedication from technology transfer through lifecycle management. From the first technical feasibility discussion to post-launch supply chain management, every programme benefits from dedicated expert engagement rather than a transactional project management interface.

Programme Summary: Nine Phases at a Glance

Phase	Key Activities	Primary Stakeholders
1. Requirements Definition	Product profile, dosage form, batch size range and regulatory market definition	Business Development, Technical Operations, Regulatory Affairs
2. Due Diligence and Capability Screening	Technical capability and regulatory certification review	Regulatory Affairs, Quality Assurance, Technical Operations
3. Site Qualification and Auditing	Pre-audit documentation request, on-site audit and Quality Agreement execution	Quality Assurance, Regulatory Affairs
4. Technical Data Package	Formulation, process, analytical and stability data compilation and gap analysis	Formulation Science, Analytical Development, Regulatory Affairs
5. Stakeholder Governance	Responsible, Accountable, Consulted and Informed matrix, governance cadences and shared milestone project plan	Programme Management and all functions
6. Technology Transfer	Engineering batches, analytical method transfer and Aseptic Process Simulation planning	Technical Operations, Quality Control, Quality Assurance
7. Process Validation and Regulatory Filing	Process Performance Qualification, media fill and regulatory variation submission	Quality Assurance, Regulatory Affairs, Contract Development and Manufacturing Organisation
8. Commercial Supply Readiness	Supply chain risk assessment, demand planning integration and batch release alignment	Supply Chain, Quality Assurance, Commercial
9. Steady-State and Lifecycle Management	Key Performance Indicator monitoring, change control and capacity planning	All functions, ongoing

Frequently Asked Questions

Discuss Your Sterile Injectable Programme with Adragos Pharma

If you are evaluating European Contract Development and Manufacturing Organisation partners for a commercial sterile injectable programme, our team is available to discuss your requirements in detail.